Autoimmune Hepatitis
Immunology·MeSH: Hepatitis, Autoimmune
Prevalence
30.0 / 100K
5 drugs in development·4 companies·3 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| VAY736 | Novartis AG (NVS) |
Phase 2(2)
Phase 1(1)
| Drug | Company |
|---|---|
| vay736 | Novartis AG (NVS) |
Preclinical(1)
| Drug | Company |
|---|---|
| jkb-122 | Biostax Corp. (BTAX) |
Compare drugs
Frequently asked questions
How many drugs are in development for Autoimmune Hepatitis?
BioSniper tracks 5 drugs in development for Autoimmune Hepatitis across 4 companies.
How many clinical trials target Autoimmune Hepatitis?
There are 3 clinical trials targeting Autoimmune Hepatitis tracked by BioSniper.
What is the prevalence of Autoimmune Hepatitis?
The estimated prevalence of Autoimmune Hepatitis is approximately 30.0 per 100,000 population.
Deep-dive into Autoimmune Hepatitis
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis